Edwards Lifesciences Corporation
NYSE:EWMedical - Devices
+$0.49 today
- Market cap
- $60.51B
- Beta
- 0.87
- P/E (TTM)
- 46.2
- EPS (TTM)
- $1.89
Volume 3.92M
Average 5.02M
EW Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Edwards Lifesciences CorporationNYSE: EW
Other Working Capital · Q2 FY2026 · quarter ended Jun 2026
Other working capital turns positive
Q2 FY2026 other working capital was $41.9M, compared with -$262.1M a year earlier. Trailing-twelve-month other working capital was -$104.8M. Over 3 fiscal years it compounded at +37.8% a year.
Context
- Other working capital amounted to 4.4% of revenue in FY2025, up 0.5 pp from a year earlier.
- Other working capital grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other working capital holds near $41.9M or moves back toward the trailing-twelve-month quarterly average of -$26.2M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (268.2M) USD
- Year-over-year change
- -25.4%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (268.2M) | -25.4% |
| FY2024 | 2024-12-31 | (213.9M) | +11.6% |
| FY2023 | 2023-12-31 | (242.1M) | -136.2% |
| FY2022 | 2022-12-31 | (102.5M) | -335.6% |
| FY2021 | 2021-12-31 | 43.5M | — |
Other Working Capital vs competitors
How EW compares with its peers on the latest reported figures
- EW's LTM Jun 2026 other working capital of $104.8M is the 2nd largest of the 6 companies compared; the peer median is $0.
- Its year-over-year change of -21.0% is the 3rd highest of 6, against a peer median of -54.8%.
- Other working capital amounts to 1.6% of revenue for EW, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $398.5M | -54.8% | -18.9% | 3.4% | |
| LTM Jun 2026 | $104.8M | -21.0% | +37.8% | 1.6% | |
| LTM Jun 2026 | $28.31M | +511.8% | -71.9% | 1.9% | |
| LTM Sep 2026 | $9.52M | -102.2% | +457.9% | 0.6% | |
| LTM Mar 2026 | $2.76M | -15.6% | -7.0% | 0.6% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding EW) | $0 | -54.8% | -13.0% | 0.6% | |
Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.5B | 1.52B | 1.4B | 4.17B | 1.07B |
| Depreciation & Amortization | 134.8M | 139.6M | 144.9M | 155.2M | 156.6M |
| Deferred Income Tax | (41.4M) | (254.5M) | (272.1M) | (323.4M) | (117.6M) |
| Stock-Based Compensation | 109.3M | 126.8M | 139.4M | 162.3M | 158.1M |
| Change in Working Capital | 145.3M | (421.4M) | (526.3M) | (259.3M) | 154.6M |
| Accounts Receivables | (112.4M) | (84.1M) | (141.2M) | 121.2M | (23M) |
| Inventory | 19M | (213.4M) | (289M) | (256.1M) | 50.7M |
| Accounts Payables | 195.2M | (21.4M) | 146M | 89.5M | 395.1M |
| Other Working Capital | 43.5M | (102.5M) | (242.1M) | (213.9M) | (268.2M) |
| Other Non-Cash Items | (119M) | 105.8M | 7.5M | (3.36B) | 174.1M |
| Operating Cash Flow | 1.73B | 1.22B | 895.8M | 542.3M | 1.6B |
| Capital Expenditures | (329.8M) | (264.8M) | (266.3M) | (252.4M) | (260.2M) |
| Acquisitions (Net) | 329.8M | 0 | (95.2M) | (1.06B) | 0 |
| Purchases of Investments | (1.89B) | (778.9M) | (105.5M) | (945.8M) | (3.14B) |
| Sales of Investments | 529.2M | 1.36B | 715.8M | 857.6M | 2.88B |
| Other Investing Activities | (359.3M) | (63.1M) | (75M) | 3.75B | (195.7M) |
| Investing Cash Flow | (1.72B) | 252.3M | 173.8M | 2.31B | (712.9M) |
| Debt Repayment | (1.8M) | (200K) | (300K) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 174.1M |
| Common Stock Repurchased | (512.8M) | (1.73B) | (879.6M) | (1.16B) | (893.4M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 158.3M | 142.8M | 168.9M | 176.4M | (237.5M) |
| Financing Cash Flow | (356.3M) | (1.58B) | (711M) | (983M) | (956.8M) |
| Effect of Forex Changes | 13.9M | 19.2M | 16.8M | 38.6M | (44.8M) |
| Net Change in Cash | (332.8M) | (94.8M) | 375.4M | 1.91B | (119.3M) |
| Free Cash Flow | 1.4B | 953.4M | 629.5M | 289.9M | 1.34B |
Edwards Lifesciences Corporation
NYSE:EW
Intrinsic Alpha fair value
Locked
Current Price
$105.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.